<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ingenol mebutate (United States and Canada: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ingenol mebutate (United States and Canada: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ingenol mebutate (United States and Canada: Not available): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="83364" href="/d/html/83364.html" rel="external">see "Ingenol mebutate (United States and Canada: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F14204999"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Picato [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F13743063"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Topical Skin Product</li></ul></div>
<div class="block doa drugH1Div" id="F13825973"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Picato gel has been discontinued in the United States for &gt;1 year.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4bb58f89-580c-47cf-bf9c-e5c96334fe50">Actinic keratosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Actinic keratosis:</b> Topical:</p>
<p style="text-indent:-2em;margin-left:4em;">Face or scalp: Apply 0.015% gel once daily to affected area for 3 consecutive days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22417254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22417254'])">Ref</a></span>); patients not achieving clearance or that experience recurrence after achieving clearance ≥8 weeks after initial treatment may benefit from a second treatment course.</p>
<p style="text-indent:-2em;margin-left:4em;">Trunk or extremities: Apply 0.05% gel once daily to affected area for 2 consecutive days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22417254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22417254'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990113"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doha drugH1Div" id="F50987431"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doe drugH1Div" id="F13825974"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F13825955"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Percentages represent face/scalp and trunk/extremities incidences unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Crusted skin (74% to 80%), dermal ulcer (≤32%), desquamation (≤90%), erythema of skin (92% to 94%), exfoliation of skin (≤90%), localized vesiculation (face/scalp: ≤56%; trunk/extremities: ≤44%), pustules (face/scalp: ≤56%; trunk/extremities: ≤44%), skin erosion (≤32%), swelling of skin (face/scalp: 79%; trunk/extremities: 64%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site pain (face/scalp: 15%, trunk/extremities: 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin infection (face/scalp: 3%; at application site)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site irritation (trunk/extremities: 4%), application site pruritus (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (face/scalp: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Periorbital edema (face/scalp: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (trunk/extremities: 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Ophthalmic: Conjunctivitis (including chemical-induced), eye pain, eyelid edema</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic contact dermatitis, cicatrix of skin (application site), dyschromia (application site), Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Skin carcinoma (literature suggests an incidence up to 9%, primarily squamous cell carcinoma of the skin) (Wang 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster infection</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (chemical), corneal injury (burn), injury to eye region (FDA 2015)</p></div>
<div class="block coi drugH1Div" id="F13825952"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hypersensitivity to ingenol mebutate or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F13825953"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic reactions: Severe reactions including erythema, crusting, swelling, vesiculation/pustulation, and erosion/ulceration may occur in the treated area. Do not apply ingenol mebutate gel until skin is healed from any prior drug or surgical treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, as well as allergic reactions leading to hospitalization, and allergic contact dermatitis, have been reported. If anaphylaxis or other clinically significant hypersensitivity reaction occurs, discontinue immediately and manage as medically appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular toxicity: Avoid treatment in the periocular area. Severe eye pain, chemical conjunctivitis, corneal burning, eyelid edema, eyelid ptosis, and periorbital edema can occur after exposure. Patients should wash their hands well immediately after applying and avoid transferring to the eye area. If accidental exposure occurs, patient should flush area with water and contact health care provider.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin cancer, nonmelanoma: Cases of rapidly growing squamous cell carcinoma have been reported, usually occurring within a few weeks of treatment completion.</p></div>
<div class="block prod-avail drugH1Div" id="F56844560"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Picato gel has been discontinued in the United States for &gt;1 year.</p></div>
<div class="block foc drugH1Div" id="F13830538"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Picato: 0.015% (3 ea [DSC]); 0.05% (2 ea [DSC]) [contains benzyl alcohol, isopropyl alcohol]</p></div>
<div class="block geq drugH1Div" id="F13825948"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322928"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Picato External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.015% (per each): $443.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per each): $665.02</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F13825976"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Apply topically to one contiguous affected area of skin using one unit-dose tube; one unit-dose tube will cover ~5 cm x 5 cm (~25 cm<sup>2</sup> or ~2 inch x 2 inch). Spread evenly then allow gel to dry for 15 minutes. Do not cover with bandages or occlusive dressings. Wash hands immediately after applying and avoid transferring gel to any other areas. Avoid washing or touching the treatment area or doing activities that cause sweating for ≥6 hours, and following this period of time, patients may wash the area with a mild soap. Not for oral, ophthalmic, or intravaginal use. Avoid application near or around the mouth and lips. Avoid transfer of gel to the periocular area. If accidental exposure occurs, flush area with water and contact health care provider.</p></div>
<div class="block use drugH1Div" id="F13743068"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Actinic keratosis:</b> Topical treatment of actinic keratosis</p></div>
<div class="block cyt drugH1Div" id="F13853563"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F13853561"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F13825950"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Systemic absorption is limited following topical administration; maternal use is not expected to result in fetal exposure.</p></div>
<div class="block brc drugH1Div" id="F13825951"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;">It is not known if ingenol mebutate is present in breast milk.</p>
<p style="text-indent:0em;margin-top:2em;">Systemic absorption is limited following topical administration; maternal use is not expected to result in exposure via breastfeeding. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Avoid direct skin-to-skin contact with treated areas to prevent accidental transfer to a breastfeeding infant.</p></div>
<div class="block mop drugH1Div" id="F54294971"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for signs/symptoms of hypersensitivity reactions; dermatologic toxicity; squamous cell carcinoma.</p></div>
<div class="block pha drugH1Div" id="F13829598"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ingenol mebutate appears to induce primary necrosis of actinic keratosis with a subsequent neutrophil-mediated inflammatory response with antibody-dependent cytotoxicity of residual disease cells; killing residual disease cells may prevent future relapse (Ramsay 2011; Siller 2010).</p></div>
<div class="block phk drugH1Div" id="F13825967"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Absorption: Absorption through the skin is minimal (with proper use); expected systemic exposure is &lt;0.1 ng/mL.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F22059500"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Picato</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Picato</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Picato</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Picato</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-22417254">
<a name="22417254"></a>Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. <i>N Engl J Med</i>. 2012;366(11):1010-1019. doi:10.1056/NEJMoa1111170<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ingenol-mebutate-united-states-and-canada-not-available-drug-information/abstract-text/22417254/pubmed" id="22417254" target="_blank">22417254</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Picato (ingenol mebutate) [prescribing information]. Madison, NJ: LEO Pharma Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21375515">
<a name="21375515"></a>Ramsay JR, Suhrbier A, Aylward JH, et al. The sap from <i>Euphorbia peplus</i> is effective against human nonmelanoma skin cancers. <i>Br J Dermatol</i>. 2011;164(3):633-636.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ingenol-mebutate-united-states-and-canada-not-available-drug-information/abstract-text/21375515/pubmed" id="21375515" target="_blank">21375515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20546215">
<a name="20546215"></a>Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. <i>Australas J Dermatol</i>. 2010;51(2):99–105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ingenol-mebutate-united-states-and-canada-not-available-drug-information/abstract-text/20546215/pubmed" id="20546215" target="_blank">20546215</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  UK Drug Safety update. Ingenol mebutate gel (Picato): suspension of the license due to risk of skin malignancy. Available at <a href="https://www.gov.uk/drug-safety-update/ingenol-mebutate-gel-picato-suspension-of-the-licence-due-to-risk-of-skin-malignancy" target="_blank">https://www.gov.uk/drug-safety-update/ingenol-mebutate-gel-picato-suspension-of-the-licence-due-to-risk-of-skin-malignancy</a>. Published February 12, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32735056">
<a name="32735056"></a>Wang Y, Lipner SR. Retrospective analysis of squamous cell carcinoma associated with ingenol mebutate reported to the US Food and Drug Administration. <i>Dermatol Ther</i>. 2020;33(6):e14114. doi:10.1111/dth.14114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ingenol-mebutate-united-states-and-canada-not-available-drug-information/abstract-text/32735056/pubmed" id="32735056" target="_blank">32735056</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 17140 Version 111.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
